SOURCE: TomoTherapy
Reports $47.6 Million of Revenue; $42.5 Million of Equipment Orders
MADISON, WI–(Marketwire – July 29, 2010) – TomoTherapy Incorporated (
advanced radiation therapy, today released financial results for the second
quarter ended June 30, 2010.
Second Quarter Results
Second quarter 2010 revenue was $47.6 million, an increase of 16% from
$41.1 million in the second quarter of 2009. Revenue from product sales
was $34.2 million in the second quarter of 2010, up 12% compared to the
same quarter last year, and revenue from service and other was $13.4
million in the second quarter of 2010, up 27% compared to the same quarter
last year. The company reported a second quarter 2010 loss from operations
of $8.4 million, a 14% decrease from the $9.7 million loss from operations
for the same period last year.
The company incurred a net loss attributable to shareholders of $6.9
million, or $0.13 per share, for the second quarter of 2010, compared to a
net loss of $7.1 million, or $0.14 per share, for the second quarter of
2009.
As of June 30, 2010, the company had $145.7 million of cash, cash
equivalents and short-term investments, representing a $3.0 million
decrease from March 31, 2010, and minimal debt. During the quarter, there
were no borrowings against the company’s credit facility.
As of June 30, 2010, the company had a revenue backlog of $139.2 million, a
4% increase from the $134.2 million backlog as of March 31, 2010. The
backlog includes $42.5 million of equipment orders received during the
second quarter of 2010. One order was removed from backlog during the
second quarter due to uncertainty surrounding the project schedule.
Backlog includes only firm orders that the company believes are likely to
ship within the next two years. Backlog does not include any revenue from
service contracts, which represents a growing portion of the company’s
overall revenue.
“Our second quarter financial results were in line with our internal
expectations and represent a solid improvement over the same period last
year,” said Fred Robertson, TomoTherapy’s CEO. “In addition, we are
pleased with the 13% increase in revenue from the first quarter of 2010 and
the $5.0 million net increase to our backlog since March 31, 2010.
Specifically, we realized a rise in new orders, which we believe reflects
the strength of our new product offerings as well as enhanced global sales
and marketing efforts. On the service side, revenue increased
significantly compared to the same period last year, due to continued
growth in the number of service contracts, and we again achieved strong
customer service rankings. We continue to take steps to enhance our
financial performance and drive toward profitability while still investing
in key product development initiatives. Importantly, our capital position
remained strong in the quarter despite the continuing challenges in the
global economy.”
Six-Month Results
For the six months ended June 30, 2010, revenue was $89.7 million, a 25%
increase from $71.7 million for the six months ended June 30, 2009.
Revenue from product sales was $63.5 million in the first half of 2010, up
23% compared to the first half of 2009, and revenue from service and other
was $26.2 million in the first half of 2010, up 31% compared to the first
half of 2009.
The company reported a year-to-date 2010 loss from operations of $14.4
million, a 39% decrease from the loss from operations of $23.7 million
during the first six months of 2009. The company incurred a net loss
attributable to shareholders of $11.6 million, or $0.22 per share, for the
six months ended June 30, 2010, compared to a net loss attributable to
shareholders of $20.1 million, or $0.40 per share, for the same period last
year.
During the first half of 2010, the company’s cash, cash equivalents and
short-term investments decreased by $8.7 million. The company’s backlog
increased by $3.4 million during the first half of 2010, from $135.8 as of
December 31, 2009 to $139.2 million as of June 30, 2010.
Outlook
The company reaffirms its revenue and earnings guidance for full-year 2010.
Management still expects 2010 revenue to be comparable to 2009 revenue of
$160 million to $180 million, with a net loss attributable to shareholders
in the range of $0.65 to $0.85 per share. Consistent with prior years,
management is not providing specific quarterly guidance. However, similar
to 2009, management anticipates that the timing of expected customer
deliveries will result in 2010 second half revenues being heavily weighted
toward the fourth quarter.
Robertson concluded, “Given our second quarter performance and expectations
for the balance of the year, we remain on track to deliver results in line
with our previously announced guidance. While there is still uncertainty
with respect to macro conditions, particularly in Europe, we are encouraged
by recent performance in North America and Asia. We also continue to make
good progress on several key initiatives, including diversifying our
product line-up and expanding our business both in North America and other
global markets. With significant interest in our TomoDirect™ and
TomoHD™ offerings, entry into new markets, and greater access to many
hospitals through new strategic Group Purchasing Organization agreements,
we believe TomoTherapy is well positioned to capitalize on the substantial
opportunity in the growing global radiation therapy market.”
Investor Conference Call
TomoTherapy will conduct a conference call regarding its second quarter
2010 results at 5:00 p.m. EDT today, July 29, 2010 (4:00 p.m. CDT). To
hear a live Webcast or replay of the call, visit the Investor Relations page at TomoTherapy.com, where it will
be archived for two weeks. To access the call via telephone, dial
1-800-260-8140 from inside the United States or
1-617-614-3672 from outside the United States, and enter pass code
35309628. The replay can be accessed by dialing 1-888-286-8010 from inside
the United States or 1-617-801-6888 from outside the United States and
entering pass code 64325104. The telephone replay will be available
through 11:59 p.m. CDT on August 5, 2010.
About TomoTherapy Incorporated
TomoTherapy Incorporated develops, markets and sells advanced radiation
therapy solutions that can be used to efficiently treat a wide variety of
cancers, from the most common to the most complex. The ring gantry-based
TomoTherapy® platform combines integrated CT imaging with conformal
radiation therapy to deliver sophisticated radiation treatments with speed
and precision while reducing radiation exposure to surrounding healthy
tissue. TomoTherapy’s suite of solutions includes its flagship Hi*Art®
treatment system, which has been used to deliver more than three million
CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment
fractions; the TomoHD™ treatment system, designed to enable cancer centers
to treat a broader patient population with a single device; and the
TomoMobile™ relocatable radiation therapy solution, designed to improve
access and availability of state-of-the-art cancer care. TomoTherapy’s
stock is traded on the NASDAQ Global Select Market under the symbol “TOMO.”
To learn more about TomoTherapy, please visit TomoTherapy.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Statements
concerning market acceptance of the company’s technology; growth drivers;
the company’s orders, revenue, backlog or earnings growth; future financial
results and any statements using the terms “should,” “believe,” “outlook,”
“expect,” “anticipate” or similar statements are forward-looking statements
that involve risks and uncertainties that could cause the company’s actual
results to differ materially from those anticipated. Such risks and
uncertainties include: demand for the company’s products; impact of sales
cycles and competitive products and pricing; the effect of economic
conditions and currency exchange rates; the company’s ability to develop
and commercialize new products; its reliance on sole or limited-source
suppliers; its ability to increase gross margins; the company’s ability to
meet U.S. Food and Drug Administration (FDA) and other regulatory agency
product clearance and compliance requirements; the possibility that
material product liability claims could harm future revenue or require the
company to pay uninsured claims; the company’s ability to protect its
intellectual property; the impact of managed care initiatives, other health
care reforms and/or third-party reimbursement levels for cancer care;
potential loss of key distributors or key personnel; risk of interruptions
to the company’s operations due to terrorism, disease or other events
beyond the company’s control; and the other risks listed from time to time
in the company’s filings with the U.S. Securities and Exchange Commission,
which by this reference are incorporated herein. TomoTherapy assumes no
obligation to update or revise the forward-looking statements in this
release because of new information, future events or otherwise.
TOMOTHERAPY INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(unaudited)
Three Months Ended Six Months Ended
June 30, June 30,
-------------------- --------------------
2010 2009 2010 2009
--------- --------- --------- ---------
Revenue:
Product $ 34,242 $ 30,552 $ 63,471 $ 51,685
Service and other 13,388 10,528 26,239 20,018
--------- --------- --------- ---------
Total revenue 47,630 41,080 89,710 71,703
--------- --------- --------- ---------
Cost of revenue:
Product 17,354 14,253 30,139 25,998
Service and other 17,818 18,312 34,509 34,651
--------- --------- --------- ---------
Total cost of revenue 35,172 32,565 64,648 60,649
--------- --------- --------- ---------
Gross profit 12,458 8,515 25,062 11,054
--------- --------- --------- ---------
Operating expenses:
Research and development 8,960 7,020 16,500 12,869
Selling, general and
administrative 11,910 11,224 22,944 21,876
--------- --------- --------- ---------
Total operating expenses 20,870 18,244 39,444 34,745
--------- --------- --------- ---------
Loss from operations (8,412) (9,729) (14,382) (23,691)
Other income (expense):
Interest income 416 695 947 1,392
Interest expense (12) (15) (23) (29)
Other expense, net (578) (107) (1,026) (363)
--------- --------- --------- ---------
Total other income (expense) (174) 573 (102) 1,000
--------- --------- --------- ---------
Loss before income tax and
noncontrolling interests (8,586) (9,156) (14,484) (22,691)
Income tax expense (benefit) 10 (318) (34) (418)
--------- --------- --------- ---------
Net loss (8,596) (8,838) (14,450) (22,273)
Noncontrolling interests 1,673 1,715 2,849 2,151
--------- --------- --------- ---------
Net loss attributable to
shareholders $ (6,923) $ (7,123) $ (11,601) $ (20,122)
========= ========= ========= =========
Weighted-average common shares
outstanding -
basic and diluted 51,713 50,592 51,640 50,592
========= ========= ========= =========
Loss per common share - basic
and diluted $ (0.13) $ (0.14) $ (0.22) $ (0.40)
========= ========= ========= =========
TOMOTHERAPY INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
(unaudited)
June 30, December 31,
2010 2009
------------ ------------
ASSETS
Cash and cash equivalents $ 99,240 $ 76,108
Short-term investments 46,434 78,225
Receivables, net 32,915 33,559
Inventories, net 53,204 47,669
Prepaid expenses and other current assets 5,507 3,633
------------ ------------
Total current assets 237,300 239,194
Property and equipment, net 18,198 18,628
Other non-current assets, net 10,588 12,429
------------ ------------
TOTAL ASSETS $ 266,086 $ 270,251
============ ============
LIABILITIES AND EQUITY
Accounts payable $ 11,896 $ 6,269
Accrued expenses 20,273 19,588
Accrued warranty 3,776 4,173
Deferred revenue 31,506 34,145
Customer deposits 11,145 13,266
------------ ------------
Total current liabilities 78,596 77,441
Other non-current liabilities 4,404 5,475
------------ ------------
TOTAL LIABILITIES 83,000 82,916
Total shareholders' equity 175,498 183,424
Noncontrolling interests 7,588 3,911
------------ ------------
TOTAL EQUITY 183,086 187,335
------------ ------------
TOTAL LIABILITIES AND EQUITY $ 266,086 $ 270,251
============ ============